NEW JERSEY and HANGZHOU, China, September 29, 2022-- Adlai Nortye Ltd. (“Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, announced that this week attended Cantor Fitzgerald's Oncology, Hematology & HemeOnc Conference.
Lars Birgerson, President of Adlai Nortye Ltd., discussed Adlai Nortye’s focus on the discovery and development of innovative cancer therapies for patients across tumor types, with multi-national R&D centers in both China and the United States. The company highlighted its most advanced drug buparlisib, a pan-PI3K inhibitor that is in a registrational trial in metastatic Head and Neck Squamous Cell Carcinoma. The company also highlighted the potential of its other pipeline drugs, palupiprant and AN4005, in solid tumors.
About Adlai Nortye
Adlai Nortye is a global clinical-stage biotechnology company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the U.S. With a strategic emphasis on oncology, the Company has built a global pipeline through collaborations and internal discovery with 7 drug candidates in development. Currently, three of them are being investigated in multiple clinical trials, including (i) Buparlisib(AN2025) which received the FDA Fast-Track designation and was in a global Phase III clinical trial; (ii) Palupiprant (AN0025), an oral EP4 antagonist which has completed Phase Ib trial in a neoadjuvant setting in locally advanced rectal cancer and is undergoing Phase 1b trial in combination with Keytruda® in patients with multiple solid tumors; and (iii) AN4005, an oral small molecule PD-L1 drug which was currently in Phase I trial that was shown to functionally overcome the inhibition derived from PD-1/L1 interaction in reporter- and human PBMC (hPBMC)-based cellular assays. In addition, Adlai Nortye also completed the first patient dosing for its Phase I clinical trial in collaboration with Roche to evaluate the triple combination of AN2025, AN0025 and Tecentriq® (PD-L1 inhibitor) for a variety of PIK3CA mutant solid tumors in September 2021 in the U.S.
Adlai Nortye has assembled an experienced management team, built its unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. Adlai Nortye is committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. The ultimate goal of the Company is to transform deadly cancer into a chronic and eventually a curable disease. For more information, please visit: www.adlainortye.com.